Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) FCF Margin % : -602.75% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Tonix Pharmaceuticals Holding's Free Cash Flow for the three months ended in Dec. 2023 was $-22.78 Mil. Tonix Pharmaceuticals Holding's Revenue for the three months ended in Dec. 2023 was $3.78 Mil. Therefore, Tonix Pharmaceuticals Holding's FCF Margin % for the quarter that ended in Dec. 2023 was -602.75%.

As of today, Tonix Pharmaceuticals Holding's current FCF Yield % is -640.77%.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's FCF Margin % or its related term are showing as below:

TNXP' s FCF Margin % Range Over the Past 10 Years
Min: -1414.75 Med: -1414.75 Max: -1414.75
Current: -1414.75

During the past 13 years, the highest FCF Margin % of Tonix Pharmaceuticals Holding was -1414.75%. The lowest was -1414.75%. And the median was -1414.75%.

TNXP's FCF Margin % is ranked worse than
79.19% of 1033 companies
in the Biotechnology industry
Industry Median: -148.24 vs TNXP: -1414.75

Tonix Pharmaceuticals Holding FCF Margin % Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding FCF Margin % Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,414.75

Tonix Pharmaceuticals Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-631.69	-602.75

Competitive Comparison of Tonix Pharmaceuticals Holding's FCF Margin %

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's FCF Margin % falls into.

Tonix Pharmaceuticals Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Tonix Pharmaceuticals Holding's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-109.898	/	7.768
	=	-1,414.75 %

Tonix Pharmaceuticals Holding's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-22.778	/	3.779
	=	-602.75 %

Tonix Pharmaceuticals Holding FCF Margin % Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304